21.11.2012 - The Dutch biotech company Kiadis BV has raised €10m in a financing round led by its largest investor.
This round was led by the Company’s largest shareholder Life Sciences Partners and supported by a large investment from DFJ-Esprit, a tech investor based in London. Other financiers included Alta Partners (San Francisco), Quest for Growth (Netherlands) and NOM, the regional development for Northern Netherlands. Kiadis Pharma is specialised on developing treatments for blood cancer and related diseases.
The company's most advanced project is ATIR, which focuses on donor immune cells in which the alloreactive T-cells that would otherwise attack the patient’s body have been selectively eliminated. The cells are infused in the patient about 30 days after the patient has undergone a stem cell transplantation in which all immune cells have been depleted from the graft of the donor.
The financing will enable Kiadis Pharma to perform a confirmatory multi-centre Phase II proof-of-concept study with its lead product and to prepare a pivotal Phase II/III study. Manfred Ruediger, CEO of Kiadis Pharma and Venture Partner at Kiadis shareholder LSP, commented: “We are delighted with the enthusiastic support from existing and new investors, which attests to the exciting clinical data generated for ATIR so far and to the progress the company has achieved over the last year. We are determined to advance ATIR in close cooperation with our clinical investigators in North America and Europe.” Kiadis Pharma merged in 2007 with the Canadian Biotech Celmed Biosciences.
26.05.2016 BigDNA relaunches as Iceni Pharmaceuticals with the aim to develop repurposed and reformulated cancer therapies. First order of business: repurpose Merck Serono’s cilengitide as a multiple myeloma treatment.
24.05.2016 One of the pioneering companies developing pharmaceuticals and diagnostics based on the gut microbiome, Enterome Bioscience, has raised €14.5m in a Series C financing round. Among the investors were Seventure and Lundbeckfond as well as Nestlé.
20.05.2016 The long awaited global review on antimicrobial resistance by economist Lord Jim O’Neill has been published. It sets out an action plan to defeat superbugs with a huge awareness campaign and rapid diagnostics to be used before antibiotics are prescribed.
18.05.2016 Bayer is deepening its involvement in CRISPR with a licensing agreement for genome editing patents. Irish partner ERS Genomics holds the rights to the CRISPR/Cas9 tech from Emmanuelle Charpentier, one of the inventors.
11.05.2016 Newly spun out company OxStem has raised £16.9m (€21.5m) to develop regenerative meds for the treatment of age-related disease. It is the largest financing for an Oxford spin-out – or any UK academic spin-out – to date.
09.05.2016 Swiss Genentech partner AC Immune has raised CHF42.7m (€38.6m) in order to advance its therapeutic and diagnostic product pipeline in Alzheimer’s disease. The news follows a recently announced R&D collaboration with Biogen.
04.05.2016 Barcelona-based epigenetics expert Oryzon Genomics has closed a debt funding round of €10.5m, bringing the total money raised since last year to €27m. The funds will serve to advance the company’s two LSD1 inhibitors in cancer and neurodegeneration.
03.05.2016 Ipsen is strengthening its ties to long-time development partner Oncodesign, a Dijon-based cancer treatment biotech. The French pharma is handing over the pre-clinical pharmacology for its oncology research programmes to Oncodesign.
29.04.2016 Swiss bank Group UBS has raised US$471m (€412m) for the UBS Oncology Impact Fund, which was set up to invest in early-stage cancer treatments. The money raised by the fund, nearly half of which comes from investors in Asia, is the largest amount ever raised for such a cancer investment fund.